COMMUNIQUÉS West-GlobeNewswire

First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026
12/05/2026
Investigator-sponsored study, conducted at the Moffitt Cancer Center, demonstrates safety and efficacy consistent with the Phase 3 IMerge trial in a broader patient population Additional presentations at EHA 2026 and [...]
Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease
12/05/2026
sNDA submission follows agreement with FDA on confirmatory trial, a requirement of the accelerated approval pathway Confirmatory trial designed to demonstrate clinical benefit of mitapivat on reducing transfusion burden [...]
BlossomHill Therapeutics to Present Initial Clinical Dose Escalation Data from the Phase 1/1b Trial of BH-30236 in Patients with R/R AML or HR-MDS at EHA2026
12/05/2026
Treatment with BH-30236, a novel CLK inhibitor, was generally well tolerated as monotherapy and in combination with venetoclax Preliminary anti-leukemic activity observed, including patients that were previously treated [...]
Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress
12/05/2026
Pivotal data from APEX trial in Advanced Systemic Mastocytosis accepted for oral presentation; Cogent’s third oral presentation of pivotal data with bezuclastinib at major medical meetings Preclinical data from [...]
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress
12/05/2026
Oral presentation of data from RALLY-MF phase 2 trial of DISC-0974 in patients with myelofibrosis and anemia Additional abstracts highlighting updates on HELIOS open label extension study of bitopertin in EPP, EPP LIGHT [...]
Ajax Therapeutics Announces Oral Presentation of Clinical Results from AJX-101, a Phase I study of AJ1-11095, a First-in-Class Type II JAK2 Inhibitor, at the European Hematology Society (EHA) 2026 Congress
12/05/2026
– Company unveils first proof-of concept clinical data of AJ1-11095 in patients with myelofibrosis who have been previously treated with a type I JAK2 Inhibitor – NEW YORK and CAMBRIDGE, Mass., May 12, 2026 (GLOBE [...]
Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias
12/05/2026
Detailed results from RISE UP Phase 3 trial of mitapivat in sickle cell disease selected for distinguished Plenary Abstracts Session Company to host investor conference call and webcast during EHA 2026 on Saturday, June [...]
MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026
12/05/2026
iNKT therapy, agenT-797, delivers context-dependent immune reprogramming showing activation in cancer and anti-inflammatory benefit in ARDS — from the same manufacturing donor batch, without genetic engineering Findings [...]
Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics
12/05/2026
– Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium’s Existing ADHD Portfolio – – Extends Collegium’s Long-Term Revenue Outlook; AZSTARYS has Expected Patent Protection [...]
Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
12/05/2026
Secured equity financing with gross proceeds of $175M in April 2026 Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. planned to initiate in second half of 2026 First-in-human Phase [...]
BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1
12/05/2026
- Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstrating the rapid and durable benefit of encaleret across key clinical parameters in ADH1 - All pre-specified primary and [...]
Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference
12/05/2026
BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced [...]
Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
12/05/2026
LONDON, May 12, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial results for [...]
Vireo Growth Inc. Announces First Quarter 2026 Results
12/05/2026
Q1 GAAP revenue of $106.2 million increased 333.5% year-over-year, driven by recently closed M&A transactions Moves to 4 th largest cannabis company on a pro forma basis by revenue Closed the Schwazze acquisition [...]
Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates
12/05/2026
On track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Presented new preclinical data for XTX601, a [...]
BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients
12/05/2026
Over 315 patients screened and over 230 patients enrolled in BriaCell’s pivotal Phase 3 Bria-ABC study of Bria-IMT plus immune checkpoint inhibitor in metastatic breast cancer Enrollment momentum continues with strong [...]
Harvard Bioscience Announces First Quarter 2026 Financial Results
12/05/2026
First Quarter 2026 Revenues of $20.8M and Gross Margin of 59% Consolidation of Manufacturing Operations Progressing on Schedule Reaffirms Full Year 2026 Financial Guidance HOLLISTON, Mass., May 12, 2026 (GLOBE NEWSWIRE [...]
Aveanna to Participate at the William Blair 46th Annual Growth Stock Conference
12/05/2026
ATLANTA, May 12, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that its management team will attend the William Blair 46 th Annual Growth Stock Conference in [...]
Compass Therapeutics to Participate in Upcoming May Investor Events
12/05/2026
BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human [...]

Pages